IPSEY - Exelixis/Bristol-Myers' drug combo shows sustained survival benefits in kidney cancer

Ipsen (OTCPK:IPSEF) said two-year follow-up data from a phase 3 CheckMate -9ER trial, showed sustained survival benefits, and health related quality of life (HRQoL) improvements with the combination of Exelixis (NASDAQ:EXEL) Cabometyx (cabozantinib) and Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) against sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). The company said that with a median follow-up of 32.9 months (25.4 months minimum), Cabometyx in combination with Opdivo continued to show superiority across efficacy goals of overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR), including increased complete response (CR) rates compared to sunitinib. For the secondary goal of median OS, the combination showed a maintained clinically meaningful improvement (37.7 months vs. 34.3 months), with a 30% reduction in the risk of death compared to sunitinib. PFS benefits, the primary goal of the study, were also maintained, with the combination continuing to double median PFS vs. sunitinib (16.6

For further details see:

Exelixis/Bristol-Myers' drug combo shows sustained survival benefits in kidney cancer